First Manhattan CO Trevi Therapeutics, Inc. Transaction History

First Manhattan CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.61 - $2.42 $1,610 - $2,420	-1,000 Reduced 66.67%	500 $0
Q3 2022 Nov 14, 2022	SELL	$1.54 - $4.28 $1,540 - $4,280	-1,000 Reduced 40.0%	1,500 $2,000
Q1 2022 May 16, 2022	SELL	$0.46 - $2.48 $460 - $2,480	-1,000 Reduced 28.57%	2,500 $5,000
Q2 2021 Aug 16, 2021	BUY	$2.0 - $2.76 $3,200 - $4,416	1,600 Added 84.21%	3,500 $7,000
Q1 2021 May 14, 2021	SELL	$2.36 - $3.55 $236 - $355	-100 Reduced 5.0%	1,900 $5,000
Q4 2020 Feb 16, 2021	BUY	$2.42 - $3.99 $2,420 - $3,990	1,000 Added 100.0%	2,000 $4,000
Q3 2020 Nov 12, 2020	BUY	$3.5 - $7.62 $3,500 - $7,620	1,000 New	1,000 $4,000

57.1M

136K

5.4K

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $226M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.